Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMRN
stocks logo

IMRN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Immuron Ltd (IMRN.O) is -104.86, compared to its 5-year average forward P/E of -24.45. For a more detailed relative valuation and DCF analysis to assess Immuron Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-24.45
Current PE
-104.86
Overvalued PE
21.98
Undervalued PE
-70.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
3.53
Current PS
2.03
Overvalued PS
6.34
Undervalued PS
0.72
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IMRN News & Events

Events Timeline

(ET)
2025-12-03
10:20:00
Trump Administration Injects $150M into xLight
select
2025-12-03
06:10:00
Immuron Signs New Research Agreement with Naval Medical Research Command
select
2025-11-05 (ET)
2025-11-05
06:23:30
Immuron Receives FDA Approval for IND of IMM-529
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-04Benzinga
UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading

  • UiPath Financial Results: UiPath Inc. shares rose 8.7% in pre-market trading after reporting third-quarter adjusted earnings of 16 cents per share and revenue of $411.11 million, both exceeding estimates.

  • Other Gainers: Several stocks saw significant pre-market gains, including Polyrizon Ltd (+158.1%), Nauticus Robotics, Inc (+34%), and Picard Medical, Inc (+22.3%), driven by positive news and developments.

  • Notable Losers: Virax Biolabs Group Ltd fell 16.2% after announcing a private placement, while Treasure Global Inc declined 13.3% following a reverse stock split and Nasdaq delisting notification.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like Axogen, Inc and Hyster-Yale, Inc also experiencing notable increases.

[object Object]
Preview
7.5
12-03Globenewswire
Immuron Secures US Military Contract for New Oral Therapeutics Targeting Campylobacter and Shigella
  • New Contract Awarded: Immuron has secured a new contract with the U.S. Department of Defense to develop oral therapeutics targeting Campylobacter and Shigella, which is expected to significantly enhance gut health protection for U.S. military personnel.
  • Vaccine Development Progress: Collaboration with the Naval Medical Research Command and Walter Reed Army Institute of Research is advancing the development of new vaccines aimed at combating Shigella infections, which cause approximately 600,000 deaths annually worldwide.
  • Clinical Trial Update: Topline results from the Uniformed Services University's clinical trial evaluating the effectiveness of IMM-124E in maintaining gut health are anticipated soon, potentially providing critical data for future military applications.
  • Strong Market Demand: With an estimated 1.5 billion episodes of diarrhea occurring globally each year, particularly in developing countries, there is a pressing need for preventative treatments, positioning Immuron's new products to fill this market gap.
[object Object]
Preview
7.5
12-03Newsfilter
Immuron Secures US Military Contract for Oral Therapeutics Development Targeting Campylobacter and Shigella
  • New Contract Award: Immuron has secured a new contract with the U.S. Department of Defense to develop two novel oral therapeutics targeting Campylobacter and Shigella, marking a significant advancement in the company's military biopharmaceutical initiatives.
  • Vaccine Development Collaboration: The collaboration with the Naval Medical Research Command and Walter Reed Army Institute of Research is advancing the development of new vaccines, utilizing Immuron's proprietary technology platform to produce hyper-immune bovine colostrum products aimed at enhancing military preventive capabilities.
  • Clinical Trial Update: Results from the Uniformed Services University's clinical trial evaluating the effectiveness of hyper-immune bovine colostrum in maintaining gut health are expected to be announced soon, potentially providing strong data support for future market promotion.
  • Global Health Impact: With an estimated 1.5 billion episodes of diarrhea leading to 2.2 million deaths annually, particularly in developing countries, Immuron's new therapies are poised to mitigate the impact of these pathogens and enhance global public health outcomes.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immuron Ltd (IMRN) stock price today?

The current price of IMRN is 1.56 USD — it has increased 0.65 % in the last trading day.

arrow icon

What is Immuron Ltd (IMRN)'s business?

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

arrow icon

What is the price predicton of IMRN Stock?

Wall Street analysts forecast IMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immuron Ltd (IMRN)'s revenue for the last quarter?

Immuron Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Immuron Ltd (IMRN)'s earnings per share (EPS) for the last quarter?

Immuron Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Immuron Ltd (IMRN)'s fundamentals?

The market is revising No Change the revenue expectations for Immuron Limited (IMRN) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -16.04%.
arrow icon

How many employees does Immuron Ltd (IMRN). have?

Immuron Ltd (IMRN) has 6 emplpoyees as of December 05 2025.

arrow icon

What is Immuron Ltd (IMRN) market cap?

Today IMRN has the market capitalization of 10.84M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free